Clinical Trial

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-08-24; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2022-02-24
Trial Details
NCT Number NCT05026749
Lead Sponsor University of Alabama at Birmingham
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Respiratory Syncytial Virus Infections
Enrollment 370 participants
Start Date 2022-02-27
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09